All In Biotech

Drug Trial Radar · NCT05362292

TReating Incontinence for Underlying Mental and Physical Health

Cognitive, Urinary, and Functional Trajectories of Older Women Using Pharmacologic Treatment Strategies for Urgency Incontinence

Last checked: Nov 20, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Oct 4, 2022

Primary completion

May 2, 2027

Study completion Aug 2, 2027

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Aging (NIA)
First posted
May 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinary incontinence and either normal or mildly impaired cognitive function at baseline.

Conditions

  • Urinary Incontinence, Urge
  • Urinary Incontinence
  • Overactive Bladder
  • Incontinence, Urge
  • Incontinence, Urinary
  • Incontinence

Interventions

  • Tolterodine Tartrate ERDrug

    Anticholinergic

  • MirabegronDrug

    Beta-3-adrenergic agonist

  • PlaceboDrug

    matching placebo pill

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in composite cognitive function over 6 months (24 weeks) of treatment, using a composite cognitive score that incorporates normalized data from all domain-specific cognitive tests.Time frame: Baseline to 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.